Is DHC Corporation profitable in 2026?

Yes. DHC reported FY2025 (ended Dec 2025) sales of about JPY99.6 billion with revenue and profit both up year-on-year, per the company's own disclosure dated 2026-03-27. Management is targeting 10% growth in FY2026 to cross JPY100 billion, per WWD Japan reporting from 2026-02-24.

Who owns DHC Corporation now?

DHC has been a wholly owned subsidiary of ORIX Corporation since ORIX completed its acquisition on January 31, 2023, for roughly JPY300 billion (about $2.3bn at the time). Founder Yoshiaki Yoshida resigned around the deal and had fully exited by end of 2023.

Could AI replace DHC Corporation's business?

Unlikely for its core. DHC's business is physical cosmetics and supplement manufacturing plus regulated OTC/quasi-drug products, which require licenses AI-only entrants cannot replicate. AI mainly threatens peripheral areas like customer service and personalization for its 16 million-plus mail-order members, not core formulation or manufacturing.

Who is DHC Corporation's biggest competitor?

FANCL Corporation and Suntory Wellness are DHC's closest direct-marketing peers in Japan's cosmetics and supplement space. Larger rivals like Shiseido, Kao, and Otsuka Holdings also compete, and Suntory Holdings announced an agreement in April 2026 to acquire Daiichi Sankyo Healthcare, consolidating scale among DHC's rivals.

Did DHC Corporation have a scandal involving its founder?

Yes. Founder Yoshiaki Yoshida made anti-Korean statements between 2016 and 2021, prompting a warning letter from the Japan Federation of Bar Associations dated March 30, 2022. He resigned as Chairman/President around ORIX's 2023 acquisition and fully exited DHC by end of 2023.

What is DHC Corporation's revenue and how big is the company?

DHC reported FY2025 (ended Dec 2025) sales of approximately JPY99.6 billion (99,603 million yen), per company disclosure dated 2026-03-27. It has over 16 million mail-order members and reports 1,459 standalone employees as of April 1, 2026.

Consumer brands · subsidiary of ORIX Corporation · Japan

DHC Corporation

Japanese mail-order cosmetics and supplement maker, owned by ORIX since 2023.

Hard to displace

Assessed 26 July 2026 · Evidence as of 26 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 26 July 2026 · Checkable from February 2027 · Every call on the record Checkpoint: FY2026 full-year results, testing whether DHC crosses ¥100bn and hits 10% growth guidance

The call

DHC keeps running on old customer habit and factory licenses while ORIX's money and bigger rivals' moves decide how much room is left.

DHC sells cosmetics and supplements mainly through mail-order to 16 million customers in Japan, backed by ORIX's financial strength and decades of regulatory permits. Bigger rivals like Suntory, Otsuka, and Shiseido could copy its products and steal customers, but DHC's real advantage comes from habit and licensing rather than something impossible to replicate. The biggest unknown is what ORIX plans to do with DHC next, whether it will sell the company, take it public, or keep it, which could change everything in the next few years.

Why

AI pressure: AI-native DTC skincare and supplement startups using personalization and chat-based skin advisors. Personalized AI skincare quizzes and bots could pull younger buyers away from DHC's catalog-style mail order model. Could AI do the core job? Unlikely.

Bigger players: Suntory Holdings. Suntory's April 2026 purchase of Daiichi Sankyo Healthcare signals bigger rivals consolidating scale DHC cannot match. Could a giant copy it? Yes, easily.

What protects it. 16 million registered mail-order members, in-house regulated manufacturing, and licenses built over 50 years of direct sales.

What would change this call

DHC's FY2026 results (reported around Feb 2027) show revenue above or below ¥100bn. Whether DHC's post-ORIX turnaround is on track or stalling against rivals.
ORIX announces an IPO, secondary sale, or strategic review of DHC. Whether ORIX intends to hold, grow, or exit DHC, reshaping its competitive backing.
Suntory's integration of Daiichi Sankyo Healthcare yields a mail-order or supplement product line overlapping DHC's core categories. Whether a larger rival is directly targeting DHC's supplement customer base.

Key numbers

FY2025 revenue ¥99.6 billion (2026-03-27)
16 million+ mail-order members (2026-03-27)
ORIX bought DHC for about ¥300 billion (2023-01-31)

Named risks

ORIX may pursue an IPO, secondary sale, or strategic review of DHC with no signal given yet. Severity: medium
Founder Yoshiaki Yoshida's past anti-Korean remarks could resurface via his new venture Yamatogokoro, launched 2023. Severity: medium
Rival consolidation, such as Suntory's 2026 acquisition of Daiichi Sankyo Healthcare, increases scale pressure on DHC. Severity: medium
DHC's moat rests on habit and licensing, not exclusivity, leaving it open to larger rivals like Otsuka, Shiseido, and Kao. Severity: high
No evidence of DHC deploying AI for personalization or customer service, risking erosion of DTC mail-order share to AI-native entrants. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Suntory Holdings	losing to	Suntory's April 2026 deal to buy Daiichi Sankyo Healthcare gives it 10 to 20x DHC's scale
Otsuka Holdings	losing to	Otsuka's group revenue vastly exceeds DHC's roughly JPY100bn scale as of FY2025
FANCL Corporation	contesting	Direct mail-order cosmetics and supplement peer running a similar playbook to DHC
Shiseido	contesting	Larger incumbent cosmetics maker with no structural barrier preventing direct competition with DHC
Kao Corporation	contesting	Major Japanese cosmetics and household goods rival competing in overlapping product categories

Questions people ask

Is DHC Corporation profitable in 2026?: Yes. DHC reported FY2025 (ended Dec 2025) sales of about JPY99.6 billion with revenue and profit both up year-on-year, per the company's own disclosure dated 2026-03-27. Management is targeting 10% growth in FY2026 to cross JPY100 billion, per WWD Japan reporting from 2026-02-24.
Who owns DHC Corporation now?: DHC has been a wholly owned subsidiary of ORIX Corporation since ORIX completed its acquisition on January 31, 2023, for roughly JPY300 billion (about $2.3bn at the time). Founder Yoshiaki Yoshida resigned around the deal and had fully exited by end of 2023.
Could AI replace DHC Corporation's business?: Unlikely for its core. DHC's business is physical cosmetics and supplement manufacturing plus regulated OTC/quasi-drug products, which require licenses AI-only entrants cannot replicate. AI mainly threatens peripheral areas like customer service and personalization for its 16 million-plus mail-order members, not core formulation or manufacturing.
Who is DHC Corporation's biggest competitor?: FANCL Corporation and Suntory Wellness are DHC's closest direct-marketing peers in Japan's cosmetics and supplement space. Larger rivals like Shiseido, Kao, and Otsuka Holdings also compete, and Suntory Holdings announced an agreement in April 2026 to acquire Daiichi Sankyo Healthcare, consolidating scale among DHC's rivals.
Did DHC Corporation have a scandal involving its founder?: Yes. Founder Yoshiaki Yoshida made anti-Korean statements between 2016 and 2021, prompting a warning letter from the Japan Federation of Bar Associations dated March 30, 2022. He resigned as Chairman/President around ORIX's 2023 acquisition and fully exited DHC by end of 2023.
What is DHC Corporation's revenue and how big is the company?: DHC reported FY2025 (ended Dec 2025) sales of approximately JPY99.6 billion (99,603 million yen), per company disclosure dated 2026-03-27. It has over 16 million mail-order members and reports 1,459 standalone employees as of April 1, 2026.

Timeline

2026-04-15Suntory Holdings announces agreement to acquire Daiichi Sankyo Healthcare, consolidating rival scale
2026-02-24WWD Japan reports FY2025 sales near JPY99.6bn and FY2026 target of 10% growth to cross JPY100bn
2024-05-08DHC unveils new corporate purpose 'Shiawase wo, futsuu ni.' and redesigned logo
2023-04-01New management structure launched under ORIX ownership, dubbed DHC's 'second founding'
2023-01-31ORIX completes acquisition of DHC for approximately JPY300 billion, making it a wholly owned subsidiary
2022-11-11ORIX executes share purchase agreement to acquire DHC
2022-03-30Japan Federation of Bar Associations issues warning letter to DHC and its chairman
2021-12DHC exits the South Korean market amid boycotts
1980DHC enters cosmetics manufacturing
1972Company founded as Daigaku Honyaku Center, a translation-outsourcing business

Head to head

DHC Corporation vs Fancl Corporation

Revision history

26 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Hermes International Compagnie Financiere Richemont Inditex (Zara)